Document is current
Any future updates will be listed below
-
Authors
Barbeira, Alvaro N.
Bonazzola, Rodrigo
Gamazon, Eric R.
Liang, Yanyu
Park, YoSon
Kim-Hellmuth, Sarah
Wang, Gao
Jiang, Zhuoxun
Zhou, Dan
Hormozdiari, Farhad
Liu, Boxiang
Rao, Abhiram
Hamel, Andrew R.
Pividori, Milton D.
Aguet, François
,
Bastarache, Lisa
Jordan, Daniel M.
Verbanck, Marie
Do, Ron
,
Stephens, Matthew
Ardlie, Kristin
McCarthy, Mark
Montgomery, Stephen B.
Segrè, Ayellet V.
Brown, Christopher D.
Lappalainen, Tuuli
Wen, Xiaoquan
Im, Hae Kyung http://orcid.org/0000-0003-0333-5685
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK20595)
National Institute of Health (R01MH107666)
- License Information
-
More Information
Article History
Received: 6 June 2020
Accepted: 18 December 2020
First Online: 26 January 2021
Ethics approval and consent to participate
: Not applicable.
: F.A. is an inventor on a patent application related to TensorQTL; S.E.C. is a co-founder, chief technology officer, and stock owner at Variant Bio; E.R.G. is on the Editorial Board of Circulation Research, and does consulting for the City of Hope/Beckman Research Institute; E.T.D. is chairman and member of the board of Hybridstat LTD.; B.E.E. is on the scientific advisory boards of Celsius Therapeutics and Freenome; G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig, MSMuTect, MSMutSig, POLYSOLVER, and TensorQTL. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics; S.B.M. is on the scientific advisory board of MyOme; D.G.M. is a co-founder with equity in Goldfinch Bio, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Merck, Pfizer, and Sanofi-Genzyme; H.K.I. has received speaker honoraria from GSK and AbbVie; T.L. is a scientific advisory board member of Variant Bio with equity and Goldfinch Bio. P.F. is a member of the scientific advisory boards of Fabric Genomics, Inc., and Eagle Genomes, Ltd. P.G.F. is a partner of Bioinf2Bio.
